Efficacy of vitamin D supplementation in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Mariam Adil, Muhammad Meeran Saleem, Sneha Vijay, Muhammad Ehsan, Isha Atiq, Eman Anwar, Malik Olatunde Oduoye
{"title":"Efficacy of vitamin D supplementation in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.","authors":"Mariam Adil, Muhammad Meeran Saleem, Sneha Vijay, Muhammad Ehsan, Isha Atiq, Eman Anwar, Malik Olatunde Oduoye","doi":"10.1097/MS9.0000000000002445","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>COVID-19 has substantial effects on respiratory health and overall well-being. Recent studies suggest vitamin D as a potential treatment, but the results are inconclusive.</p><p><strong>Objective: </strong>The authors conducted a systematic review of randomized controlled trials (RCTs) to examine the link between vitamin D and patients with COVID-19.</p><p><strong>Data sources: </strong>The authors searched electronic databases PubMed, Cochrane, CINAHL, EMBASE and Google Scholar from their inception till August 2023.</p><p><strong>Study selection: </strong>Inclusion criteria used in our systematic review include: (1) patients who tested positive for COVID-19, (2) intervention was vitamin D supplementation, (3) the comparator was either a placebo, standard care of treatment, or, no treatment, (4) at least one of the clinical outcomes of interest were investigated, (5) study design being RCTs.</p><p><strong>Data extraction: </strong>Two independent reviewers manually extracted information from selected articles, including study characteristics, patient characteristics, and the primary outcomes: all-cause mortality, ICU and hospital stay length and secondary outcomes: mechanical ventilation, supplemental oxygen, ICU admission, and adverse events. Risk ratios or mean differences and 95% CIs were calculated using a random-effects model.</p><p><strong>Data synthesis: </strong>The authors' analysis included 14 RCTs with 2165 patients. Vitamin D significantly reduced ICU admissions and lowered the need for mechanical ventilation compared to placebo. However, it did not significantly affect hospital stay length, ICU stay length, mechanical ventilation duration, mortality, or the need for supplemental oxygen.</p><p><strong>Conclusion: </strong>Vitamin D does not significantly improve certain clinical outcomes, such as hospital and ICU stay length, for patients with COVID-19. However, it still may be significantly beneficial in decreasing the burden on intensive care services.</p>","PeriodicalId":8025,"journal":{"name":"Annals of Medicine and Surgery","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444563/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Medicine and Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/MS9.0000000000002445","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Context: COVID-19 has substantial effects on respiratory health and overall well-being. Recent studies suggest vitamin D as a potential treatment, but the results are inconclusive.
Objective: The authors conducted a systematic review of randomized controlled trials (RCTs) to examine the link between vitamin D and patients with COVID-19.
Data sources: The authors searched electronic databases PubMed, Cochrane, CINAHL, EMBASE and Google Scholar from their inception till August 2023.
Study selection: Inclusion criteria used in our systematic review include: (1) patients who tested positive for COVID-19, (2) intervention was vitamin D supplementation, (3) the comparator was either a placebo, standard care of treatment, or, no treatment, (4) at least one of the clinical outcomes of interest were investigated, (5) study design being RCTs.
Data extraction: Two independent reviewers manually extracted information from selected articles, including study characteristics, patient characteristics, and the primary outcomes: all-cause mortality, ICU and hospital stay length and secondary outcomes: mechanical ventilation, supplemental oxygen, ICU admission, and adverse events. Risk ratios or mean differences and 95% CIs were calculated using a random-effects model.
Data synthesis: The authors' analysis included 14 RCTs with 2165 patients. Vitamin D significantly reduced ICU admissions and lowered the need for mechanical ventilation compared to placebo. However, it did not significantly affect hospital stay length, ICU stay length, mechanical ventilation duration, mortality, or the need for supplemental oxygen.
Conclusion: Vitamin D does not significantly improve certain clinical outcomes, such as hospital and ICU stay length, for patients with COVID-19. However, it still may be significantly beneficial in decreasing the burden on intensive care services.
背景:COVID-19 对呼吸系统健康和整体健康有很大影响。最近的研究表明维生素 D 是一种潜在的治疗方法,但结果尚无定论:作者对随机对照试验(RCT)进行了系统回顾,以研究维生素 D 与 COVID-19 患者之间的联系:作者检索了从开始到 2023 年 8 月的 PubMed、Cochrane、CINAHL、EMBASE 和 Google Scholar 等电子数据库:系统综述的纳入标准包括(1)COVID-19检测呈阳性的患者;(2)干预措施为维生素D补充剂;(3)比较对象为安慰剂、标准治疗方法或无治疗方法;(4)至少调查了一项临床结果;(5)研究设计为RCT:两名独立审稿人手动提取所选文章的信息,包括研究特点、患者特点、主要结果:全因死亡率、重症监护室和住院时间以及次要结果:机械通气、补充氧气、重症监护室入院和不良事件。采用随机效应模型计算风险比或平均差异及 95% CI:作者的分析包括14项研究,共2165名患者。与安慰剂相比,维生素 D 能明显减少入住 ICU 的人数,并降低机械通气的需求。然而,维生素 D 对住院时间、重症监护室住院时间、机械通气时间、死亡率或补充氧气的需求并无明显影响:结论:维生素 D 并不能明显改善 COVID-19 患者的某些临床结果,如住院时间和重症监护室停留时间。结论:维生素 D 并不能明显改善 COVID-19 患者的某些临床预后,如住院时间和重症监护室留院时间,但仍能明显减轻重症监护服务的负担。